Sugi Predict

Sugi Predict / Compounds / SCHEMBL12786202

SCHEMBL12786202

SCHEMBL12786202

C[C@H](c1ccccc1)N([C@H](C)c1ccccc1)p1oc2ccc3ccccc3c2c2c(ccc3ccccc32)o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ HPGD P15428 3/20 0.35
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ MAPT P10636 3/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ ABCG2 Q9UNQ0 3/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP1A1 P04798 1/20 0.35
▸ FYN P06241 1/20 0.35
▸ MAPK3 P27361 1/20 0.35
▸ AHR P35869 1/20 0.35
▸ PAX8 Q06710 1/20 0.35
▸ HNF4A P41235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2858384 1.00 L3MBTL1 (0.35) L3MBTL1RAB9ANPC1KDM4EHPGD
SCHEMBL14254609 1.00 L3MBTL1 (0.35) L3MBTL1RAB9ANPC1KDM4EHPGD
SCHEMBL31043202 1.00 L3MBTL1 (0.35) L3MBTL1RAB9ANPC1KDM4EHPGD
SCHEMBL4841739 1.00 L3MBTL1 (0.35) L3MBTL1RAB9ANPC1KDM4EHPGD
SCHEMBL29871051 1.00 L3MBTL1 (0.35) L3MBTL1RAB9ANPC1KDM4EHPGD
SCHEMBL31642941 1.00 L3MBTL1 (0.35) L3MBTL1RAB9ANPC1KDM4EHPGD
SCHEMBL14001438 0.94 L3MBTL1 (0.34) L3MBTL1RAB9ANPC1KDM4EHPGD
SCHEMBL14075526 0.88 UGT2B7 (0.40) MEN1KMT2AABCG2CYP1A2TSHR
SCHEMBL13296110 0.88 UGT2B7 (0.40) MEN1KMT2AABCG2CYP1A2TSHR
SCHEMBL16193207 0.86 L3MBTL1 (0.34) L3MBTL1RAB9ANPC1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072582-B2 Substituted pyrrolidines as G-protein coupled receptor 43 agonists EPICS THERAPEUTICS (BE) 2021-07-27 — — US disclosed
US-10889599-B2 1,1-diborylalkyl-1-metal compounds, preparation method thereof, and their applications toward synthesis of 1,1-diboronate ester compounds POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2021-01-12 — — US disclosed
US-20200347016-A1 SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS EPICS THERAPEUTICS (BE) 2020-11-05 — — US disclosed
US-20190263837-A1 1,1-Diborylalkyl-1-Metal Compounds, Preparation Method Thereof, and Their Applications Toward Synthesis of 1,1-Diboronate Ester Compounds POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2019-08-29 — — US disclosed
US-9309165-B2 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof H. LUNDBECK A/S (DK) 2016-04-12 — — US disclosed
WO-2016029216-A2 METHOD FOR PRODUCING AMIDINE DERIVATIVES BIOCRYST PHARMACEUTICALS, INC. (US) 2016-02-25 — — WO disclosed
US-20150336867-A1 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof H. LUNDBECK A/S (DK) 2015-11-26 — — US disclosed
US-8586498-B2 Homogeneous asymmetric hydrogenation catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-11-19 — — US disclosed
US-8586498-B2 Homogeneous asymmetric hydrogenation catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-11-19 — — US disclosed
US-8497400-B2 Homogeneous asymmetric hydrogenation process TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-07-30 — — US disclosed
US-20100137615-A1 Homogeneous Asymmetric Hydrogenation Process TAKASAGO INTERNATIONAL CORPORATION (JP) 2010-06-03 — — US disclosed
US-20100121089-A1 Methods for preparing dioranozinc compounds CHARETTE ANDRE 2010-05-13 — — US disclosed
US-20100121089-A1 Methods for preparing dioranozinc compounds CHARETTE ANDRE 2010-05-13 — — US disclosed
US-20090203927-A1 Homogeneous asymmetric hydrogenation catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-08-13 — — US disclosed
US-20090203927-A1 Homogeneous asymmetric hydrogenation catalyst TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-08-13 — — US disclosed
US-20090054689-A1 PHOSPHORAMIDITE LIGAND AND PRODUCTION METHOD OF ALLYLIC AMINE USING THE SAME Carreira, Erick M. (CH) 2009-02-26 — — US disclosed
US-20080227978-A1 Converting a carbonyl group within a substrate to a chiral alcohol moiety by reacting the carbonyl containing substrate with an organoaluminium reagent in the presence of a Group 5-12 transition metal based catalyst which is complexed with a chiral ligand; excellent yields THE UNIVERSITY OF NOTTINGHAM 2008-09-18 — — US disclosed
US-20080227978-A1 Converting a carbonyl group within a substrate to a chiral alcohol moiety by reacting the carbonyl containing substrate with an organoaluminium reagent in the presence of a Group 5-12 transition metal based catalyst which is complexed with a chiral ligand; excellent yields THE UNIVERSITY OF NOTTINGHAM 2008-09-18 — — US disclosed
EP-1911516-A1 HOMOGENEOUS ASYMMETRIC HYDROGENATION CATALYST Takasago International Corporation (JP) 2008-04-16 — — EP disclosed
US-20070259774-A1 Enantioselective Phosphoramidite Compounds and Catalysts YALE UNIVERSITY (US) 2007-11-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137615-A1 Homogeneous Asymmetric Hydrogenation Process HDHD5, HHAT, HVCN1 L3MBTL1 2923/4885RAB9A 2082/4885NPC1 1764/4885
US-20090054689-A1 PHOSPHORAMIDITE LIGAND AND PRODUCTION METHOD OF ALLYLIC AMINE USING THE SAME ADH5, SELENOI, ADH1A L3MBTL1 2667/4885RAB9A 4261/4885NPC1 4771/4885
US-20090203927-A1 Homogeneous asymmetric hydrogenation catalyst HDHD5, HHAT, HACL2 L3MBTL1 2627/4885RAB9A 2049/4885NPC1 2029/4885
US-20200347016-A1 SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS GPR119, GPR52, GPR88 L3MBTL1 4616/4885RAB9A 928/4885NPC1 737/4885
US-20070259774-A1 Enantioselective Phosphoramidite Compounds and Catalysts AKR1C3, PCNA, AKR1C4 L3MBTL1 1463/4885RAB9A 2571/4885NPC1 3697/4885
US-20100121089-A1 Methods for preparing dioranozinc compounds ZRANB2, PRMT1, RDX L3MBTL1 1670/4885RAB9A 2251/4885NPC1 1904/4885
US-11072582-B2 Substituted pyrrolidines as G-protein coupled receptor 43 agonists GPR119, GPR52, GPR88 L3MBTL1 4616/4885RAB9A 928/4885NPC1 737/4885
US-20190263837-A1 1,1-Diborylalkyl-1-Metal Compounds, Preparation Method Thereof, and Their Applications Toward Synthesis of 1,1-Diboronate Ester Compounds DBI, BCL3, ORAI3 L3MBTL1 1950/4885RAB9A 2535/4885NPC1 455/4885
US-20150336867-A1 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof CYP2D6, UGT1A6, IDO1 L3MBTL1 1198/4885RAB9A 4250/4885NPC1 697/4885
US-10889599-B2 1,1-diborylalkyl-1-metal compounds, preparation method thereof, and their applications toward synthesis of 1,1-diboronate ester compounds DBI, BCL3, ORAI3 L3MBTL1 1950/4885RAB9A 2535/4885NPC1 455/4885
US-20080227978-A1 Converting a carbonyl group within a substrate to a chiral alcohol moiety by reacting the carbonyl containing substrate with an organoaluminium reagent in the presence of a Group 5-12 transition metal based catalyst which is complexed with a chiral ligand; excellent yields ADH5, ADH1C, CYP2E1 L3MBTL1 3533/4885RAB9A 3968/4885NPC1 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback